文献速递生殖医学

胰高血糖素样肽-1在生殖中的作用:从生理学到治疗前景

The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
PubMed 文献 · Hum Reprod Update · 2019-01-01

本文为叙述性综述,检索PubMed至2019年2月1日,纳入6项观察性研究、24项干预性研究、4例病例报告及3篇综述。结果提示GLP-1及其类似物在哺乳动物生殖中多起刺激作用,GLP-1受体激动剂和DPP-4抑制剂在临床前模型可逆转多囊卵巢形态,在PCOS女性中降低雄激素水平,初步临床数据显示可改善月经规律和生育率。

要点

  • GLP-1可能是连接生殖与代谢系统的重要调节信号。
  • GLP-1受体激动剂和DPP-4抑制剂在临床前模型可逆转多囊卵巢形态。
  • 初步临床数据显示GLP-1受体激动剂改善超重/肥胖PCOS女性月经规律和生育率。

核心结论

  • GLP-1受体激动剂和DPP-4抑制剂在糖尿病和肥胖相关生育力低下治疗中显示前景,但需更大规模干预性研究确立孕前干预的作用。

研究设计与样本

  • 叙述性综述,检索PubMed数据库至2019年2月1日,最终纳入6项观察性研究(3项临床前和3项人体)、24项干预性研究(9项临床前和15项人体)、4例病例报告以及1篇系统综述和2篇叙述性综述。

主要发现

  • GLP-1及其模拟物在哺乳动物生殖中多起刺激作用,且不限于体重减轻。
  • GLP-1在受肥胖、糖尿病和多囊卵巢综合征影响的性腺和子宫内膜中似乎具有抗炎和抗纤维化作用。
  • GLP-1受体激动剂和DPP-4抑制剂在临床前模型可逆转多囊卵巢形态,并降低PCOS女性血清雄激素浓度及其生物利用度。
  • 初步干预性临床研究数据提示,超重和/或肥胖PCOS女性在孕前接受GLP-1受体激动剂治疗可改善月经规律并提高生育率。

临床怎么用

  • 作者认为,GLP-1受体激动剂和DPP-4抑制剂在糖尿病和肥胖相关生育力低下治疗中显示前景。
  • 作者建议,需更大规模干预性研究确立孕前GLP-1基础治疗的作用,评估肥胖、PCOS和糖尿病相关生育问题的生育结局。
  • 作者指出,不同GLP-1受体激动剂的剂量和暴露时间-反应潜在影响需进一步探索。
  • 作者建议,未来研究应探究GLP-1对生殖结局的性别特异性差异,尤其是男性性腺观察结果最为矛盾。

局限性

  • 需更大规模干预性研究确立孕前GLP-1基础治疗的作用。
  • 不同GLP-1受体激动剂的剂量和暴露时间-反应潜在影响需进一步探索。
  • 未来研究应探究GLP-1对生殖结局的性别特异性差异,尤其是男性性腺观察结果最为矛盾。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) have become firmly established in the treatment of type 2 diabetes and obesity, disorders frequently associated with diminished reproductive health. Understanding of the role of GLP-1 and GLP-1 RAs in reproduction is currently limited and largely unaddressed in clinical studies. OBJECTIVE AND RATIONALE: The purpose of this narrative review is to provide a comprehensive overview of the role of GLP-1 in reproduction and to address a therapeutic perspective that can be derived from these findings. SEARCH METHODS: We performed a series of PubMed database systemic searches, last updated on 1 February 2019, supplemented by the authors' knowledge and research experience in the field. A search algorithm was developed incorporating the terms glucagon-like peptide-1, GLP-1, glucagon-like peptide-1 receptor, GLP-1R, or incretins, and this was combined with terms related to reproductive health. The PICO (Population, Intervention, Comparison, Outcome) framework was used to identify interventional studies including GLP-1 RAs and dipeptidyl peptidase-4 (DPP-4) inhibitors, which prevent the degradation of endogenously released GLP-1. We identified 983 potentially relevant references. At the end of the screening process, we included 6 observational (3 preclinical and 3 human) studies, 24 interventional (9 preclinical and 15 human) studies, 4 case reports, and 1 systematic and 2 narrative reviews. OUTCOMES: The anatomical distribution of GLP-1 receptor throughout the reproductive system and observed effects of GLP-1 in preclinical models and in a few clinical studies indicate that GLP-1 might be one of the important modulating signals connecting the reproductive and metabolic system. The outcomes show that there is mostly stimulating role of GLP-1 and its mimetics in mammalian reproduction that goes beyond mere weight reduction. In addition, GLP-1 seems to have anti-inflammatory and anti-fibrotic effects in the gonads and the endometrium affected by obesity, diabetes, and polycystic ovary syndrome (PCOS). It also seems that GLP-1 RAs and DPP-4 inhibitors can reverse polycystic ovary morphology in preclinical models and decrease serum concentrations of androgens and their bioavailability in women with PCOS. Preliminary data from interventional clinical studies suggest improved menstrual regularity as well as increased fertility rates in overweight and/or obese women with PCOS treated with GLP-1 RAs in the preconception period. WIDER IMPLICATIONS: GLP-1 RAs and DPP-4 inhibitors show promise in the treatment of diabetes and obesity-related subfertility. Larger interventional studies are needed to establish the role of preconception intervention with GLP-1 based therapies, assessing fertility outcomes in obesity, PCOS, and diabetes-related fertility problems. The potential impact of the dose- and exposure time-response of different GLP-1 RAs need further exploration. Future research should also investigate sex-specific variability of GLP-1 on reproductive outcomes, in particular on the gonads where the observations in males are most conflicting.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019. PMID: 31260047. doi:10.1093/humupd/dmz019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。